Pricing Log in Create free account

Lineage Cell Therapeutics, Inc. (LCTX) vs Vanda Pharmaceuticals Inc. (VNDA)

Lineage Cell Therapeutics, Inc. and Vanda Pharmaceuticals Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and Vanda Pharmaceuticals Inc. are of similar size ($256.4M and $250.5M). Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against 6.02%. Vanda Pharmaceuticals Inc. has the higher net margin (−127.4% vs −246.6%) and the lower return on invested capital (−217.6% vs −186.8%). Across the 18 metrics below, Lineage Cell Therapeutics, Inc. leads on 11 and Vanda Pharmaceuticals Inc. on 7.

Valuation

Metric LCTX VNDA Biotechnology median
P/E n/m n/m 8.50
P/S 18.69 1.13 9.71
P/B 4.09 1.10 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 14.81 0.35 9.21
Earnings yield (14.67%) (114.89%) (33.15%)
Free cash flow yield (9.98%) (63.04%) (25.50%)

Profitability

Metric LCTX VNDA Biotechnology median
Gross margin 99.46% 93.74% 65.16%
Operating margin (205.23%) (86.07%) 0.00%
Net margin (246.58%) (127.41%) 0.00%
Free cash flow margin (186.43%) (70.93%) 0.00%
Return on equity (60.35%) (77.81%) (56.36%)
Return on assets (32.75%) (53.00%) (48.04%)
Return on invested capital (186.79%) (217.59%) 0.00%

Growth

Metric LCTX VNDA Biotechnology median
Revenue growth (TTM) 19.87% 6.02% 6.02%
EPS growth (last fiscal year) (211.11%) (1,033.33%) 30.26%
Revenue growth, 5-year CAGR 51.46% (2.73%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LCTX VNDA Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 6.61 1.61 4.72
Net debt to EBITDA 2.64 1.84 0.96

Dividend

Metric LCTX VNDA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LCTX VNDA Biotechnology median
Market cap 250.45m 256.36m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack